Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Slack

Showing results (371-380 of 472) with videos related to

Pageof 48
Sort By:
Molecular Therapy. Nucleic Acids|November 24, 2025
MicroRNA-21 is a potential therapeutic agent targeting <i>Tgfbi</i> and mitigating high-fat-diet-induced liver disease and cancerUrmila Jagtap, Anan Quan, Yuho Ono, et al.
Cell|March 16, 2005
RAS is regulated by the let-7 microRNA familySteven M Johnson, Helge Grosshans, Jaclyn Shingara, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in micePhong Trang, Jason F Wiggins, Christopher L Daige, et al.
RNA (New York, N.Y.)|December 13, 2018
Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factorAlan L Jiao, Roberto Perales, Neil T Umbreit, et al.
Journal of Biotechnology|April 29, 2008
Expression of a modified Mannheimia haemolytica GS60 outer membrane lipoprotein in transgenic alfalfa for the development of an edible vaccine against bovine pneumonic pasteurellosisRaymond W H Lee, Mette Cornelisse, Asma Ziauddin, et al.
Cancer Gene Therapy|August 24, 2022
Correction to: MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister stateWen Cai Zhang, Nicholas Skiados, Fareesa Aftab, et al.
Pharmacology|February 3, 2025
Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of CancerKimberly D Herman, Ian Holyer, Duncan C Humphries, et al.
Frontiers in Immunology|September 13, 2023
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1Joseph Mabbitt, Ian D Holyer, James A Roper, et al.
Pathogens (Basel, Switzerland)|March 26, 2022
Trash to Treasure: How Insect Protein and Waste Containers Can Improve the Environmental Footprint of Mosquito Egg ReleasesMegan J Allman, Aidan J Slack, Nigel P Abello, et al.
Bioorganic & Medicinal Chemistry|November 4, 2018
Triazole-linked transition state analogs as selective inhibitors against V. cholerae sialidaseTeri J Slack, Wanqing Li, Dashuang Shi, et al.
Pageof 48

Showing results (371-380 of 472) with videos related to

Sort By:
Pageof 48
Molecular Therapy. Nucleic Acids|November 24, 2025
MicroRNA-21 is a potential therapeutic agent targeting <i>Tgfbi</i> and mitigating high-fat-diet-induced liver disease and cancerUrmila Jagtap, Anan Quan, Yuho Ono, et al.
Cell|March 16, 2005
RAS is regulated by the let-7 microRNA familySteven M Johnson, Helge Grosshans, Jaclyn Shingara, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 24, 2011
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in micePhong Trang, Jason F Wiggins, Christopher L Daige, et al.
RNA (New York, N.Y.)|December 13, 2018
Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factorAlan L Jiao, Roberto Perales, Neil T Umbreit, et al.
Journal of Biotechnology|April 29, 2008
Expression of a modified Mannheimia haemolytica GS60 outer membrane lipoprotein in transgenic alfalfa for the development of an edible vaccine against bovine pneumonic pasteurellosisRaymond W H Lee, Mette Cornelisse, Asma Ziauddin, et al.
Cancer Gene Therapy|August 24, 2022
Correction to: MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister stateWen Cai Zhang, Nicholas Skiados, Fareesa Aftab, et al.
Pharmacology|February 3, 2025
Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of CancerKimberly D Herman, Ian Holyer, Duncan C Humphries, et al.
Frontiers in Immunology|September 13, 2023
Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1Joseph Mabbitt, Ian D Holyer, James A Roper, et al.
Pathogens (Basel, Switzerland)|March 26, 2022
Trash to Treasure: How Insect Protein and Waste Containers Can Improve the Environmental Footprint of Mosquito Egg ReleasesMegan J Allman, Aidan J Slack, Nigel P Abello, et al.
Bioorganic & Medicinal Chemistry|November 4, 2018
Triazole-linked transition state analogs as selective inhibitors against V. cholerae sialidaseTeri J Slack, Wanqing Li, Dashuang Shi, et al.
Pageof 48